Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003107 · ClinicalTrials.gov registry record · Phase 1
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
A Phase 1 study of Breast Cancer and Ovarian Cancer, sponsored by Indiana University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00003107 is a Phase 1 study of Breast Cancer and Ovarian Cancer that has completed, run by Indiana University School of Medicine. The trial reports 1 study location across 1 state.
The verdict
NCT00003107, a Phase 1 study of Breast Cancer and Ovarian Cancer, has completed, sponsored by Indiana University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 in treating patients who have hematologic cancer or solid tumor.
Conditions Studied
Interventions
- BIOLOGICAL recombinant interleukin-12
Study Locations (1)
Indiana
- Indiana University Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003107
The ClinicalTrials.gov registry entry for NCT00003107 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Indiana University School of Medicine, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which recombinant interleukin-12 is the first listed.
NCT00003107 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT00003107 about?
NCT00003107 is a clinical study titled "Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors". RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 in treating patients who have hematologic cancer or solid tumor.
What is the current status of trial NCT00003107?
This trial is currently completed. It is a Phase 1 study. The study started on 1997-10.
What conditions does trial NCT00003107 study?
This clinical trial studies the following conditions: Breast Cancer, Ovarian Cancer, Lymphoma, Leukemia, Myelodysplastic Syndromes.
What interventions are being tested in trial NCT00003107?
The interventions under investigation include: recombinant interleukin-12 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003107?
This trial is sponsored by Indiana University School of Medicine, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003107 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.